Get the Stockscreener App
21.79
1.13%
-0.25
After Hours:
21.79
Sarepta Therapeutics Inc stock is traded at $21.79, with a volume of 2.16M.
It is down -1.13% in the last 24 hours and down -6.20% over the past month.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
See More
Previous Close:
$22.04
Open:
$22.37
24h Volume:
2.16M
Relative Volume:
0.78
Market Cap:
$2.30B
Revenue:
$2.20B
Net Income/Loss:
$-842.79M
P/E Ratio:
-2.5823
EPS:
-8.4382
Net Cash Flow:
$-332.39M
1W Performance:
+3.42%
1M Performance:
-6.20%
6M Performance:
+16.71%
1Y Performance:
-65.77%
1-Day Range:
$21.04
$22.66
1-Week Range:
$20.30
$22.66
52-Week Range:
$10.41
$63.92
Sarepta Therapeutics Inc Stock (SRPT) Company Profile
Name
Sarepta Therapeutics Inc
Sector
Industry
Phone
617-274-4000
Address
215 FIRST STREET, CAMBRIDGE, MA
Compare SRPT vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
21.79 | 2.33B | 2.20B | -842.79M | -332.39M | -8.4382 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Resumed | Barclays | Equal Weight |
| Dec-09-25 | Initiated | Wedbush | Outperform |
| Nov-05-25 | Upgrade | Mizuho | Neutral → Outperform |
| Sep-22-25 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jul-29-25 | Upgrade | Barclays | Underweight → Equal Weight |
| Jul-29-25 | Initiated | Bernstein | Mkt Perform |
| Jul-29-25 | Reiterated | H.C. Wainwright | Sell |
| Jul-29-25 | Upgrade | JP Morgan | Underweight → Neutral |
| Jul-29-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-28-25 | Downgrade | Barclays | Equal Weight → Underweight |
| Jul-25-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-24-25 | Initiated | Citigroup | Sell |
| Jul-23-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-22-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jul-21-25 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-21-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jul-21-25 | Downgrade | Mizuho | Outperform → Neutral |
| Jul-21-25 | Downgrade | Needham | Hold → Underperform |
| Jul-21-25 | Downgrade | UBS | Buy → Neutral |
| Jul-18-25 | Downgrade | Needham | Buy → Hold |
| Jun-20-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-18-25 | Downgrade | TD Cowen | Buy → Hold |
| Jun-17-25 | Initiated | Wolfe Research | Peer Perform |
| Jun-16-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jun-16-25 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-16-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jun-16-25 | Downgrade | H.C. Wainwright | Neutral → Sell |
| Jun-16-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-16-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jun-06-25 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| May-08-25 | Downgrade | Evercore ISI | Outperform → In-line |
| Apr-11-25 | Initiated | Wells Fargo | Overweight |
| Apr-02-25 | Upgrade | H.C. Wainwright | Sell → Neutral |
| Mar-31-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-11-25 | Initiated | Deutsche Bank | Hold |
| Nov-27-24 | Reiterated | Needham | Buy |
| Nov-25-24 | Initiated | H.C. Wainwright | Sell |
| Nov-07-24 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-21-24 | Initiated | Jefferies | Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Jul-29-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jun-26-24 | Downgrade | Citigroup | Buy → Neutral |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| May-28-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-14-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-31-24 | Initiated | BMO Capital Markets | Outperform |
| Dec-13-23 | Resumed | Citigroup | Buy |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Nov-21-23 | Initiated | Wedbush | Outperform |
| Oct-31-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Oct-31-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-23-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Apr-26-23 | Initiated | SMBC Nikko | Outperform |
| Apr-04-23 | Initiated | Citigroup | Buy |
| Mar-01-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-22-22 | Reiterated | BTIG Research | Buy |
| Dec-16-22 | Upgrade | UBS | Neutral → Buy |
| Apr-04-22 | Resumed | Cantor Fitzgerald | Overweight |
| Jan-05-22 | Reiterated | Needham | Buy |
| Dec-09-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-05-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-15-21 | Upgrade | Guggenheim | Neutral → Buy |
| Aug-05-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Neutral |
| Jan-12-21 | Downgrade | Citigroup | Buy → Neutral |
| Jan-11-21 | Downgrade | UBS | Buy → Neutral |
| Jan-08-21 | Downgrade | JP Morgan | Overweight → Underweight |
| Jan-08-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-08-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-11-20 | Initiated | Berenberg | Hold |
| Oct-28-20 | Initiated | UBS | Buy |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Aug-20-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| Mar-31-20 | Initiated | Mizuho | Buy |
| Nov-01-19 | Initiated | Guggenheim | Buy |
| Aug-21-19 | Reiterated | Needham | Buy |
| Jul-09-19 | Reiterated | Morgan Stanley | Overweight |
| Jul-01-19 | Reiterated | RBC Capital Mkts | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Mar-11-19 | Reiterated | Credit Suisse | Outperform |
| Oct-12-18 | Initiated | Bernstein | Outperform |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-26-18 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-14-18 | Resumed | BofA/Merrill | Buy |
| Sep-06-18 | Initiated | Credit Suisse | Outperform |
| Aug-01-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-21-18 | Reiterated | Robert W. Baird | Outperform |
| Jun-20-18 | Reiterated | Needham | Buy |
| Jun-19-18 | Reiterated | H.C. Wainwright | Buy |
View All
Sarepta Therapeutics Inc Stock (SRPT) Latest News
Sarepta, Amylyx and Neumora look ahead to key catalysts as Q1 earnings roll in - BioSpace
Sarepta Therapeutics Q1 2026 Earnings Preview — May 6, Street Expects $1.05 EPS - AlphaStreet
Are These 5 Biotech Stocks Set to Beat Q1 Earnings Estimates? - TradingView
Do Sarepta Therapeutics’ (SRPT) Bullish Earnings Forecasts and Vanguard Stake Hint at a Shifting Risk Profile? - Sahm
Sarepta (SRPT) Appoints New Acting Director for Biologics Evalua - GuruFocus
MSN Money - MSN
Vanguard Capital Management (NASDAQ: SRPT) reports 5.11% stake in Sarepta Therapeutics - Stock Titan
Sarepta Therapeutics (SRPT) price target decreased by 16.58% to 25.25 - MSN
Why is Sarepta Therapeutics (SRPT) up 24.2% since last earnings report? - MSN
Vanguard Portfolio Management (NASDAQ: SRPT) holds 6.75M shares (6.43%) - Stock Titan
Sarepta Therapeutics (SRPT) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
Precision Trading with Sarepta Therapeutics Inc. (SRPT) Risk Zones - Stock Traders Daily
M&T Bank Corp Acquires Shares of 83,348 Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Sarepta Therapeutics (SRPT) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Why Sarepta Therapeutics Stock Is Rising Nearly 5% Premarket - MSN
Sarepta Therapeutics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Sarepta Therapeutics stock sinks further Tuesday, after halting shipment of bestselling drug Elvidys - MSN
Sarepta’s Elevidys to Remain on Market With New FDA Warning - MSN
Sarepta Therapeutics, Inc. (SRPT) Stock Analysis: Navigating Biotech Volatility with Strategic Growth Potential - DirectorsTalk Interviews
Retail Bulls Stick With Sarepta After 8-Year-Old Patient’s Death Deemed Unrelated To DMD Gene Therapy - MSN
Sarepta Therapeutics Inc (HAM:AB3A) Stock Price, Trades & News - GuruFocus
Sarepta gains on data for muscular dystrophy therapies - MSN
Sarepta sells Arrowhead stock, activates $100M milestone payment - MSN
Sarepta to soon submit SNDAs for traditional approval for Duchenne treatments - msn.com
Sarepta cut to Underperform at BofA on Elevidys concerns - MSN
Sarepta to continue Elevidys shipments despite FDA request to halt - MSN
SRPT DEADLINE ALERT: ROSEN, NATIONAL TRIAL COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class ActionSRPT - TMX Newsfile
[ARS] Sarepta Therapeutics, Inc. SEC Filing - Stock Titan
Sarepta Therapeutics (NASDAQ: SRPT) outlines 2026 equity and ESPP plus CEO transition - Stock Titan
Sarepta Stock Slides Premarket After New FDA Warning Shrinks Market For Its $3.2M DMD Gene Therapy - MSN
Sarepta Loses Bid to Rehear Regenxbio DNA Patent Case Decision - Bloomberg Law News
Sarepta Therapeutics (SRPT) price target decreased by 10.97% to 22.48 - MSN
A Look At Sarepta Therapeutics (SRPT) Valuation After Recent Share Price Volatility - Yahoo Finance
Full Fed. Circ. Passes On Sarepta's Patent Rehearing Bid - Law360
OCGN's Gene-Agnostic Strategy Could Reset Retinal Therapy - TradingView
Sarepta Therapeutics to Announce First Quarter 2026 Financial Results - Business Wire
Sarepta Therapeutics, Inc. $SRPT Shares Purchased by Cwm LLC - MarketBeat
SRPT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Opinion: As Duchenne innovation booms, let’s ensure it becomes real progress - BioSpace
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
KROS 2026 Watchlist: 3 Catalysts That Could Reset Sentiment - TradingView
KROS Stock: Does the Takeda Deal Lower Dilution Risk in 2026? - TradingView
Sarepta Therapeutics, Inc. (SRPT) Stock Analysis: Exploring the Future of RNA-Targeted Therapeutics with Promising Forward P/E - DirectorsTalk Interviews
A Look At Sarepta Therapeutics (SRPT) Valuation After Roche’s New Global Elevidys Phase 3 Trial - Sahm
Technical Reactions to SRPT Trends in Macro Strategies - Stock Traders Daily
Roche plots route to EMA approval for DMD gene therapy - BioWorld News
H.C. Wainwright reiterates Sarepta stock Sell rating at $5 target By Investing.com - Investing.com Canada
DNA Patent Eligibility Under Spotlight in Sarepta’s En Banc Bid - Bloomberg Law News
SRPT Reiterated by HC Wainwright & Co. -- Rating Maintained at S - GuruFocus
Sarepta/ Roche Duchenne therapy to face new late-stage trial targeting EU nod - MSN
HC Wainwright Reaffirms "Sell" Rating for Sarepta Therapeutics (NASDAQ:SRPT) - MarketBeat
Sarepta Therapeutics Inc Stock (SRPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):